EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A pharmacovigilance study on probiotic preparations based on the FDA Adverse Event Reporting System from 2005 to 2023

Yitong Wang, Weifu Tan, Xuyang Li, Guangli Yang, Yunxiao Wang, Jing Liao, Aner Lu, Guoqing Zhang, Kuidai Chen, Liling Yang, Wei Li

Frontiers in Cellular and Infection Microbiology · 2025

DOI: 10.3389/fcimb.2025.1455735 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2025. Verfasst von Yitong Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neonatology, Binhaiwan Central Hospital of Dongguan, Dongguan, China. Hauptthemen laut MEDLINE: Probiotics, Pharmacovigilance, Adverse Drug Reaction Reporting Systems, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Probiotics are recognized as beneficial foods, but adverse reactions reported by individuals still exist. This study aims to analysis adverse events (AE) related to probiotics from the FAERS database from the first quarter (Q1) of 2005 to the fourth quarter (Q4) of 2023.

Methods

The AE data related to probiotic from the 2005 Q1 to the 2023 Q4 were collected. R language was applied to analyze the standardized AE data and three algorithms including the reporting odds ratio (ROR), the proportional reporting ratio (PRR) and the empirical Bayes geometric mean (EBGM) were used to identify AE signals.

Results

In this study, 10,698,312 reports were collected from the FAERS database, of which 74 probiotic-related adverse events were reported. About one third of the reported cases were older than 60 years.36.36% of the reported cases required Hospitalization. A total of 285 preference terms (PTS) and 15 system organ classes (SOC) were identified. In the overall analysis, only 9 PTs and 2 SOCs met significant disproportionality for all three algorithms simultaneously. SOCs included Gastrointestinal disorders (N=97, ROR=5.3, PRR=3.84, EBGM=3.84) and Hepatobiliary disorders (N=9, ROR =3.39, PRR=3.32, EBGM=3.32). PTs included Gastrointestinal pain (ROR=77.76, PRR=76.69, EBGM=76.63), Hypophagia (ROR=24.13, PRR=23.88, EBGM=28.88), and Hepatobiliary disorders (N=97, ROR=5.3, PRR=3.84, EBGM=3.84) and Flatulence (ROR=23.75, PRR=23.28, EBGM=23.27) were the top four highest. Meanwhile, s found new unique adverse signals such as Agitation (ROR=12.48, PRR=12.32, EBGM=12.32) and Anxiety (ROR=4.10, PRR=4.04, EBGM=4.04). Additionally, subgroup analyses were performed to identify AE signals based on gender and age. Metabolism and nutrition disorders (N=6, ROR=3.21, PRR=3.04, EBGM=3.04) and Asthenia (N=3, ROR=5.9, PRR=5.71, EBGM=5.71) were unique AE signal for the male group.

Conclusion

Although, the risk of adverse reactions arising from the application of probiotics cannot be ignored. However, However, the results of this FAERS-based study continue to support the overall safety of probiotic preparations. It is necessary to pay attention to the potential influence of factors such as gender and age on the effects and adverse reactions of probiotic application in basic research and clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProbioticsPharmacovigilanceAdverse Drug Reaction Reporting SystemsDrug-Related Side Effects and Adverse ReactionsHumansMaleFemaleMiddle AgedUnited StatesAgedAdultUnited States Food and Drug AdministrationYoung AdultAdolescentChildDatabases, FactualChild, PreschoolInfantAged, 80 and overAlgorithms

Stichwörter der Autor:innen

FAERSadverse drug reactionsadverse eventsagegenderpharmacovigilanceprobiotic

Autor:innen und Institutionen

  • Department of Neonatology, Binhaiwan Central Hospital of Dongguan, Dongguan, China.
  • Department of Pediatric, The First Clinical Medical College of Jinan University, The First Affiliated Hospital of Jinan University, Guangzhou, China.
  • Department of Central Laboratory, Binhaiwan Central Hospital of Dongguan, Dongguan, China.
  • Dongguan Key Laboratory of Prevention and Treatment of Critical Illness, Binhaiwan Central Hospital of Dongguan, Dongguan, China.

Zitieren

APA

Wang, Y., Tan, W., Li, X., Yang, G., Wang, Y., Liao, J., Lu, A., Zhang, G., Chen, K., Yang, L., & Li, W. (2025). A pharmacovigilance study on probiotic preparations based on the FDA Adverse Event Reporting System from 2005 to 2023. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1455735

Vancouver

Wang Y, Tan W, Li X, Yang G, Wang Y, Liao J, et al. A pharmacovigilance study on probiotic preparations based on the FDA Adverse Event Reporting System from 2005 to 2023. Frontiers in Cellular and Infection Microbiology. 2025. doi:10.3389/fcimb.2025.1455735

BibTeX
@article{Wang2025,
  author = {Wang, Yitong and Tan, Weifu and Li, Xuyang and Yang, Guangli and Wang, Yunxiao and Liao, Jing and Lu, Aner and Zhang, Guoqing and Chen, Kuidai and Yang, Liling and Li, Wei},
  title = {A pharmacovigilance study on probiotic preparations based on the FDA Adverse Event Reporting System from 2005 to 2023},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2025},
  doi = {10.3389/fcimb.2025.1455735}
}
Kostenlos starten →